Skip to main content
. 2002 Jan;46(1):89–94. doi: 10.1128/AAC.46.1.89-94.2002

TABLE 3.

Resistance profiles of viral clones constructed by site-directed mutagenesisa

Mutation(s) at codons Mutant NRTI resistance profileb
Zidovudine
Lamivudine
Abacavir
RF n RF n RF n
44 MW01 2.0 (1.2) 5 1.3 (0.4) 16 1.3 (0.5) 15
118 MW02 1.0 (0) 5 1.9 (1.0) 7 1.2 (0.3) 6
184 MW03 1.4 (0.5) 5 >100 (NA) 16 1.5 (0.6) 15
44/118 MW04 1.2 (0.3) 5 6.2 (2.6) 5 2.2 (0.6) 5
44/184 MW05 1.2 (0.3) 5 >100 (NA) 15 3.1 (1.2) 14
118/184 MW06 1.0 (0) 5 >100 (NA) 7 1.8 (0.6) 6
44/118/184 MW07 1.0 (0) 5 >100 (NA) 7 3.1 (1.3) 7
41/210/211/215 MW08 >100 (NA) 6 3.0 (0.6) 7 3.8 (0.8) 8
41/44/118/210/211/215 MW09 >100 (NA) 4 6.2 (1.8) 5 4.7 (1.9) 7
41/184/210/211/215 MW10 51.0 (24.0) 4 >100 (NA) 5 8.0 (3.7) 7
41/44/118/184/210/211/215 MW11 32.2 (20.6) 5 >100 (NA) 6 7.9 (2.3) 8
a

Mutations that were inserted into the pNL4-3 backbone were M41L, E44D, V118I, M184V, L210W, R211K, and T215Y. Recombinant viruses from viral clones with 211R and 214L (44/118/210/215, 44/118/184/215, 41/44/118/184/215, and 44/118/184/210/215) replicated so poorly that resistance testing could not be performed.

b

RF, fold increase in IC50 compared with the nonresistant reference virus NL4-3; n, number of independent runs for each phenotypic resistance testing; NA, not applicable, because endpoint of resistance was not determined. Standard errors are included in parentheses.

HHS Vulnerability Disclosure